Spyre Therapeutics (SYRE) director receives 8,026 stock options exercisable at $72.51

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Laurie Stelzer received a grant of stock options covering 8,026 shares of common stock. The options carry an exercise price of $72.51 per share and expire on May 27, 2036.

The award will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics' 2027 annual meeting of stockholders, as long as Stelzer continues to serve the company through that vesting date. Following this grant, she holds 8,026 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stelzer Laurie

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,026	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,026 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 8,026 options Exercise price: $72.51 per share Expiration date: May 27, 2036 +3 more

6 metrics

Option grant size 8,026 options Stock Option (Right to Buy) granted to director

Exercise price $72.51 per share Conversion or exercise price of the options

Expiration date May 27, 2036 Option expiration date

Vesting date trigger May 27, 2027 Earlier of this date or 2027 annual meeting

Underlying shares 8,026 shares Common stock underlying the options

Options held after grant 8,026 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 72.5100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest and become fully exercisable upon the earlier of May 27, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-05-27T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stelzer Laurie

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.51	05/27/2026		A		8,026		(1)	05/27/2036	Common Stock	8,026	$0	8,026	D

Explanation of Responses:

1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Spyre Therapeutics (SYRE) director Laurie Stelzer report on this Form 4?

Laurie Stelzer reported receiving a grant of stock options for 8,026 shares of Spyre Therapeutics common stock. The options were awarded at an exercise price of $72.51 per share as compensation and are held directly, with no shares bought or sold in the market.

What are the key terms of Laurie Stelzer’s Spyre Therapeutics (SYRE) stock option grant?

The grant covers 8,026 shares with an exercise price of $72.51 per share and an expiration date of May 27, 2036. These options represent the right, but not the obligation, to purchase Spyre Therapeutics common stock at that fixed price if they vest.

When do Laurie Stelzer’s Spyre Therapeutics (SYRE) options vest?

The options will vest and become fully exercisable on the earlier of May 27, 2027 or the date of Spyre Therapeutics’ 2027 annual stockholders meeting. Vesting is conditioned on Stelzer maintaining continuous service to the company through the applicable vesting date.

Did Laurie Stelzer buy or sell Spyre Therapeutics (SYRE) shares in this Form 4?

No open-market buying or selling occurred in this Form 4. Laurie Stelzer received a compensation-related stock option award, coded as a grant (A), which is classified as an acquisition of derivative securities rather than a market trade in Spyre Therapeutics shares.

How many Spyre Therapeutics (SYRE) options does Laurie Stelzer hold after this transaction?

After this transaction, Laurie Stelzer holds 8,026 stock options directly. Each option is tied to one share of Spyre Therapeutics common stock, giving her the right to purchase that many shares at $72.51 per share if the options vest and are exercised.